McCain/Schumer Generic Bill Would End 30-Month Stay Of Approval
Executive Summary
The revised McCain/Schumer generic drug bill eliminates the automatic stay of approval under current patent challenge procedures.
You may also be interested in...
GPhA CEO-Designate Jaeger Has Legal, Regulatory Background
Generic Pharmaceutical Association President & CEO Kathleen Jaeger brings experience in legal and regulatory analysis that could help the trade association in its relations with FDA and in legislative drafting
GPhA CEO-Designate Jaeger Has Legal, Regulatory Background
Generic Pharmaceutical Association President & CEO Kathleen Jaeger brings experience in legal and regulatory analysis that could help the trade association in its relations with FDA and in legislative drafting
Patent Listing Review Should Be FDA Function, Rep. DeLauro Suggests
FDA should review patents before they are listed in the "Orange Book," members of the House Agriculture Appropriations Subcommittee suggested March 21